Charles River Laboratories Intl. (NYSE:CRL) vs. Intrexon (NYSE:XON) Head-To-Head Comparison
Charles River Laboratories Intl. (NYSE:CRL) and Intrexon (NASDAQ:XON) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
This table compares Charles River Laboratories Intl. and Intrexon’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories Intl.||8.94%||22.01%||7.38%|
Charles River Laboratories Intl. has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.
This is a summary of recent ratings for Charles River Laboratories Intl. and Intrexon, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories Intl.||0||5||10||0||2.67|
Charles River Laboratories Intl. presently has a consensus target price of $147.75, suggesting a potential upside of 13.62%. Intrexon has a consensus target price of $19.67, suggesting a potential upside of 205.86%. Given Intrexon’s higher possible upside, analysts plainly believe Intrexon is more favorable than Charles River Laboratories Intl..
Insider & Institutional Ownership
94.4% of Charles River Laboratories Intl. shares are held by institutional investors. Comparatively, 75.7% of Intrexon shares are held by institutional investors. 1.8% of Charles River Laboratories Intl. shares are held by company insiders. Comparatively, 44.0% of Intrexon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Charles River Laboratories Intl. and Intrexon’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories Intl.||$2.27 billion||2.80||$226.37 million||$6.03||21.57|
|Intrexon||$160.57 million||6.49||-$509.34 million||($1.37)||-4.69|
Charles River Laboratories Intl. has higher revenue and earnings than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than Charles River Laboratories Intl., indicating that it is currently the more affordable of the two stocks.
Charles River Laboratories Intl. beats Intrexon on 10 of the 14 factors compared between the two stocks.
Charles River Laboratories Intl. Company Profile
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.